Patents by Inventor Thomas Boyle
Thomas Boyle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7067532Abstract: The invention provides a compound of Formula (Ia), or a pharmaceutically acceptable salt pro-drug or solvate thereof. The invention also provides a process for the preparation of a compound of Formula (Ia), pharmaceutical compositions of a compound of Formula (Ia) and methods for the treatment or prevention of cancer comprising administering an effective amount of a compound of Formula (Ia).Type: GrantFiled: October 26, 2001Date of Patent: June 27, 2006Assignee: AstraZenecaInventors: Francis Thomas Boyle, Keith Hopkinson Gibson, Kevin Michael Foote
-
Publication number: 20060137061Abstract: A new and distinct cultivar of Boltonia plant named ‘Masbolimket’ characterized by its single inflorescence form, violet-colored ray florets, yellow-colored disc florets, dark green-colored foliage, freely branching character, and medium upright growth habit.Type: ApplicationFiled: December 20, 2004Publication date: June 22, 2006Inventor: Thomas Boyle
-
Patent number: 7030123Abstract: The invention provides a compound of Formula (I). Wherein R1, R2, R3, R10 and R11 have the meanings given in the description. Such compounds are predicted to cause the selective destruction of tumour vasculature. They may therefore be used to inhibit and/or reverse, and/or alleviate symptoms of angiogenesis and/or any disease state associated with angiogenesis.Type: GrantFiled: May 25, 2001Date of Patent: April 18, 2006Assignee: AstraZeneca ABInventors: Jean-Claude Arnould, Thomas Geoffrey Bird, Francis Thomas Boyle, David Charles Blakey
-
Patent number: 6946468Abstract: The present invention relates to inhibitors of ras farnesylation of the Formula I wherein: R1 is for example H and further values as defined in the specification; R2 is for example H and further values as defined in the specification; R3 is for example H or a substituent having values as defined in the specification; p is 0-3 in which R3 values can be the same or different; L is a linking moiety for example —CH2—NH— and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing upto 5 heteroatoms where the heteroatoms are independently selected from O, N & S; or a —S—S— dimer thereof when R2?H; or a N-oxide or a pharmaceutically-acceptable salt, prodrug or solvate thereof. Processes for their preparation their use as therapeutic agents and pharmaceutical compositions containing them.Type: GrantFiled: August 13, 1997Date of Patent: September 20, 2005Assignee: Zeneca LimitedInventors: Francis Thomas Boyle, James Michael Wardleworth
-
Patent number: 6777438Abstract: This invention relates to compounds of formula (I) that inhibit farnesylation of gene products through inhibition of the enzyme farnesyl-protein transferase (FPTase). The invention also relates to methods of manufacturing the compounds, pharmaceutical compositions and methods of treating diseases, especially cancer, which are mediated through farnesylation.Type: GrantFiled: June 20, 2002Date of Patent: August 17, 2004Assignee: AstraZeneca ABInventors: James Michael Wardleworth, Francis Thomas Boyle, Zbigniew Matusiak
-
Publication number: 20040110775Abstract: The present invention relates to a series of CDK-inhibiting purine derivatives of structural formula (I), or a pharmaceutically acceptable salt and/or prodrug form thereof, wherein: X is O, S or CHRX where RX is H or C1-14 alkyl; D is NZ1Z2 where Z1 is selected from H, C1-4 alkyl, C1-4 hydroxyalkyl, an unsubstituted or substituted aryl or heteroaryl, and an unsubstituted or substituted aralkyl or heteroaralkyl group, and Z2 is selected from an unsubstituted or substituted aryl or heteroaryl, and an unsubstituted or substituted aralkyl or heteroaralkyl group; A is selected from H, C1-4 alkyl, C1-4 alkoxy, hydroxy, CH2(CH2)nOH (n=1-4), and NRa1Ra2 where Ra1 and Ra2 are each independently H or C1-4 alkyl; B is selected from H, halo, C1-4 alkyl, C1-4 alkoxy, CF3, an optionally substituted aryl or an optionally substituted aralkyl, and a hydroxy group that may undergo a C═O tautomeric rearrangement; and Y comprises an unsubstituted or substituted 4- to 8-membered carbocyclic or heterocyclic ring, optioType: ApplicationFiled: January 6, 2004Publication date: June 10, 2004Inventors: Roger John Griffin, Alan Hilary Calvert, Nicola Jane Curtin, Bernard Thomas Golding, Ian Robert Hardcastle, David Richard Newell, Philip John Jewsbury, Francis Thomas Boyle, Jane Anne Endicott, Martin Edward Mantyla Noble
-
Publication number: 20040029898Abstract: The invention provides a compound of Formula (Ia), or a pharmaceutically acceptable salt. prodrug or solvate thereof. The invention also provides a process for the preparation of a compound of Formula (Ia), pharmaceutical compositions of a compound of Formula (Ia) and methods for the treatment or prevention of cancer comprising administering an effective amount of a compound of Formula (Ia).Type: ApplicationFiled: May 2, 2003Publication date: February 12, 2004Inventors: Francis Thomas Boyle, Keith Hopkinson Gibson, Kevin Michael Foote
-
Publication number: 20030220495Abstract: The present invention relates to inhibitors of ras farnesylation of Formula (1), wherein T is of Formula (1) or (2) or (3), A is aryl or heteroaryl; B is aryl or heteroaryl; X and Y represent hydrogen, or both X and Y can represent a single bond (so as to form a double bond); R1 represents a group of Formula (II) or (III), the group of Formula (II) or Formula (III) (having L or D configuration at the chiral alpha carbon in the corresponding free amino acid); R2 represents hydrogen, aryl or heteroaryl; Z represents a direct bond, methylene, ethylene, vinylene, oxy, —CH2—O— or —O—CH2—; and R3—R4, p and r are as defined in the specification or a pharmaceutically-acceptable salt, prodrug or solvate thereof. Processes for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them. A particular use is in cancer therapy.Type: ApplicationFiled: February 11, 2002Publication date: November 27, 2003Applicant: Zeneca Limited and Zeneca Pharma S.A.Inventors: Francis Thomas Boyle, Gareth Morse Davies, James Michael Wardleworth, Jean-Claude Arnould
-
Publication number: 20030216356Abstract: The invention provides a compound of Formula (I) wherein: R1 and R2 are independently selected from hydrogen, halogen, —CN, a hydrocarbyl group or a group of Formula (II); wherein W is aryl or a heterocyclic group, R4 is independently select from hydrogen, halogen, —OH, amino, alkanoylamino, —OPO3H2, or a hydrocarbyl group, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified or two R4 groups together form an optionally substituted cyclic or heterocyclic group; X is selected from $M(y) S+—, +—O—+, —+S(O)+—, —+S(O2)+— and —+NH—; p is an integer from 0 to 4; and q is an integer from 1 to 4; R3 and R10 are independently selected from hydrogen, lower alkyl or a group of Formula (IV): wherein Y is selected from +NH+—, —$M(Y)O$M(Y)— or a bond; Z is selected from +NH+—, —+O&ngr;&mdashType: ApplicationFiled: November 13, 2002Publication date: November 20, 2003Inventors: Jean-Claude Arnould, Thomas Geoffrey Bird, Francis Thomas Boyle, David Charles Blakey
-
Publication number: 20030096842Abstract: This invention relates to compounds of formula (I) that inhibit farnesylation of gene products through inhibition of the enzyme farnesyl-protein transferase (FPTase). The invention also relates to methods of manufacturing the compounds, pharmaceutical compositions and methods of treating diseases, especially cancer, which are mediated through farnesylation.Type: ApplicationFiled: June 20, 2002Publication date: May 22, 2003Inventors: James Michael Wardleworth, Francis Thomas Boyle, Zbigniew Matusiak
-
Publication number: 20030083348Abstract: 1 This invention relates to compounds of formula (1) that inhibit farnesylation of gene products through inhibition of the enzyme farnesyl-protein transferase (FPTase). The invention also relates to methods of manufacturing the compounds, pharmaceutical compositions and methods of treating diseases, especially cancer, which are mediated through farnesylation.Type: ApplicationFiled: April 17, 2002Publication date: May 1, 2003Inventors: James Michael Wardleworth, Francis Thomas Boyle, Zbigniew Matusiak
-
Patent number: 6541491Abstract: Pharmaceutical compositions comprising an inhibitor of ras farnesylation of formula (I) wherein, R1 is for example H and further values as defined in the specification; R2 is for example H and further values as defined in the specification; R3 is for example H or a substituent having values as defined in the specification; p is 0-3 in which R3 values can be the same or different; L is a linking moiety for example —CO—NH2— and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N and S; or a —S—S-dimer thereof when R2=H; or an enantiomer, diastereoisomer, pharmaceutically acceptable salt, prodrug or solvate thereof together with a pharmaceutically acceptable diluent or carrier. A particular use is cancer therapy.Type: GrantFiled: November 30, 2000Date of Patent: April 1, 2003Assignee: Zeneca LimitedInventors: David Huw Davies, Francis Thomas Boyle, James Michael Wardleworth, Peter Wedderburn Kenny, Peter Beverley Scholes, Zbigniew Stanely Matusiak
-
Patent number: 6414145Abstract: The present invention relates to inhibitors of ras farnesylation of Formula (I), wherein T is of Formula (1) or (2) or (3); A is aryl or heteroaryl; B is aryl or heteroaryl; X and Y represent hydrogen, or both X and Y can represent a single bond (so as to form a double bond); R1 represents a group of Formula (II) or (III), the group of Formula (II) or Formula (III) (having L or D configuration at the chiral alpha carbon in the corresponding free amino acid); R2 represents hydrogen, aryl or heteroaryl; Z represents a direct bond, methylene, ethylene, vinylene, oxy, —CH2—O— or —O—CH2—; and R3—R4, p and r are as defined in the specification or a pharmaceutically-acceptable salt, prodrug or solvate thereof. Processes for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.Type: GrantFiled: July 28, 1999Date of Patent: July 2, 2002Assignees: Zeneca Limited, Zeneca Pharma S.A.Inventors: Francis Thomas Boyle, Gareth Morse Davies, James Michael Wardleworth, Jean-Claude Arnould
-
Patent number: 6232338Abstract: Pharmaceutical compositions comprising an inhibitor of ras farnesylation of formula (I) wherein, R1 is for example H and further values as defined in the specification; R2 is for example H and further values as defined in the specification; R3 is for example H or a substituent having values as defined in the specification; p is 0-3 in which R3 values can be the same or different; L is a linking moiety for example —CO—NH2— and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N and S; or a —S—S— dimer thereof when R2=H; or an enantiomer, diastereoisomer, pharmaceutically acceptable salt, prodrug or solvate thereof together with a pharmaceutically acceptable diluent or carrier. A particular use is cancer therapy.Type: GrantFiled: February 3, 1998Date of Patent: May 15, 2001Assignee: Zeneca LimitedInventors: David Huw Davies, Francis Thomas Boyle, James Michael Wardleworth, Peter Wedderburn Kenny, Peter Beverley Scholes, Zbigniew Stanely Matusiak
-
Patent number: 5985281Abstract: A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprising a prodrug convertible under the influence of the mutated enzyme to the antineoplastic drug. The mutated enzyme is a mutated form of a natural host enzyme which recognizes its natural substrate by an ion pair interaction with the substrate, wherein the mutated enzyme and prodrug have structures such that the polarity of the mutated enzyme/prodrug ion pair interaction is reversed relative to the natural host enzyme/natural substrate ion pair interaction. The first component is substantially non-immunogenic in the host and the prodrug second component is not significantly convertible into antineoplastic drug in the host by natural unmutated host enzyme.Type: GrantFiled: June 23, 1997Date of Patent: November 16, 1999Assignee: Zeneca LimitedInventors: Christopher John Taylorson, Hendrikus Johannes Eggelte, Antonio Tarragona-Fiol, Brian Robert Rabin, Francis Thomas Boyle, John Frederick Hennam, David Charles Blakey, Peter Robert Marsham, David William Heaton, David Huw Davies, Anthony Michael Slater, Laurent Francois Andre Hennequin
-
Patent number: 5789417Abstract: The invention relates to tricyclic compounds of formula (I) ##STR1## wherein R.sup.1 is hydrogen, amino, (1-4C)alkyl, (1-4C)alkoxy, hydroxy-(1-4C)alkyl or fluoro-(1-4C)alkyl; R.sup.2 is hydrogen, (1-4C)alkyl, (3-4C)alkenyl, (3-4C)alkynyl, hydroxy-(2-4C)alkyl, halogeno-(2-4C)alkyl or cyano-(1-4C)alkyl; Ar is optionally-substituted phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl; and R.sup.3 includes a group of the formula --NHCH(CO.sub.2 H)--A.sup.1 --Y.sup.1 wherein A.sup.1 is (1-6C)alkylene and Y.sup.1 is carboxy, tetrazol-5-yl, N-?(1-4C)alkylsulphonyl!carbamoyl, N(phenylsulphonyl)carbamoyl, tetrazol-5-ylthio, tetrazol-5-ylsulphinyl or tetrazol-5-ylsulphonyl; or pharmaceutically-acceptable salts or esters thereof; to processes for their manufacture; to pharmaceutical compositions containing them; and to their use as anti-cancer agents.Type: GrantFiled: June 28, 1995Date of Patent: August 4, 1998Assignees: Zeneca Limited, British Technology Group Ltd.Inventors: Francis Thomas Boyle, James William Crook, Zbigniew Stanley Matusiak
-
Patent number: 5747499Abstract: Cyclopentaquinazoline of the formula (I): ##STR1## wherein R.sup.1 is hydrogen, amino, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 hydroxyalkyl or C.sub.1-4 fluoroalkyl;wherein R.sup.2 is hydrogen, C.sub.1-4 alkyl, C.sub.3-4 alkenyl, C.sub.3-4 alkynyl, C.sub.2-4 hydroxyalkyl, C.sub.2-4 halogenoalkyl or C.sub.1-4 cyanoalkyl;Ar.sup.1 is phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, C.sub.1-4 alkyl and C.sub.1-4 alkoxy; andwherein R.sup.3 is a group of the formula:--A.sup.1 --Ar.sup.2 --A.sup.2 --Y.sup.1in which A.sup.1, A.sub.2, Y.sup.1 and Ar.sub.2 are defined in claim 1;or a pharmaceutically acceptable salt or ester there of are of therapeutic value particularly in the treatment of cancer.Type: GrantFiled: October 29, 1996Date of Patent: May 5, 1998Assignee: British Technology Group LimitedInventors: Vassilios Bavetsias, Francis Thomas Boyle, Laurent Francois Andre Hennequin, Jonathan Hugh Marriott
-
Patent number: 5473855Abstract: A system for securely placing threaded caps on threaded containers. The system includes a cap feeding device which facilitates the initial placement of caps on container necks. After initial placement, the cap and container are brought into engagement with a spindle assembly which grips the cap and prevents rotation of the container. The spindle assembly engages a is brought into contact with a rotation inducing device, which causes the tightening of the cap onto the container neck. The chuck of the spindle assembly and the rotation inducing device each have the ability to prevent overtightening of the cap onto the container. In addition, the cap and container are specially configured to facilitate initial placement in a manner which reduces the possibility of misalignment.Type: GrantFiled: August 9, 1994Date of Patent: December 12, 1995Inventors: Walter E. Hidding, Douglas J. Hidding, Robert D. Hidding, H. Thomas Boyles